Cagrilintide
A once-weekly long-acting amylin analog, usually studied combined with semaglutide (CagriSema).
Investigational (phase 3, with semaglutide as CagriSema); not approved.
Used for
- Weight loss, alone or with a GLP-1
- Fullness after meals
How it works
Amylin is a hormone released with insulin; it signals fullness in the brainstem and slows the stomach, working alongside GLP-1.
Half-life: about 7–8 days
What the research shows
- REDEFINE 1 (68 weeks): cagrilintide 2.4 mg + semaglutide 2.4 mg weekly lost 20.4% of body weight vs 3.0% on placebo.
- Alone, in a 26-week phase 2 dose-finding trial (0.3–4.5 mg weekly): 6–10.8% weight loss, the most at 4.5 mg (vs 9.0% on liraglutide 3 mg); nausea rose with dose.
Dosing
Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.
Work out the units to draw for your vial →Side effects
- Nausea, especially after a dose step
- Constipation or diarrhea
- Reflux, burping
- Lower appetite and thirst: dehydration risk
Cautions
- With a GLP-1, side effects add up: step each one separately.
- Research-chemical vials have no quality control: purity, dose and sterility vary. Third-party testing helps but is no guarantee.
Storage
Unmixed powder: freezer or fridge, away from light.
Once mixed with bacteriostatic water: fridge; the common rule is to use it within 28 days.
There is no label or published stability data for this one, so treat these as habits, not limits.
Stability once mixed
A lipidated amylin analog: a fatty-acid side chain built for weekly dosing. No label or pen data for a vial you mix.
Heat, shaking, freezing a mixed vial, light and many needle punctures all speed breakdown. Toss it if it turns cloudy, grows specks or changes color.
More in Weight & metabolic
Reference only, not medical advice. Written for this app from the cited research. Doses marked community-reported are not from trials.